Abstract
The Tennagen test has been evaluated in "normal" subjects, patients with cancer (predominantly colorectal) and patients with non-malignant disease. The incidence of positive values was found to be higher in patients with clinically active cancer than in those with benign conditions or normal subjects. In our hands the test fell far short of the 90% reliability previously claimed. This may be partly due to an underestimate of the upper normal limit in earlier studies. A small series of follow-up studies after resection for colorectal cancer have so far failed to reveal any advantage to be gained by Tennagen tests over existing methods, but these studied will be continued.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Pentycross, C. The Tennessee antigen test. An evaluation in cancer and non-cancer patients and normal subjects. Br J Cancer 45, 223–229 (1982). https://doi.org/10.1038/bjc.1982.37
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.37
This article is cited by
-
Determination of TPA levels in breast cancer and controls
Klinische Wochenschrift (1983)